{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"RP2D for zanubrutinib was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 320 mg QD","groups":[{"description":"Five dose regimens of zanubrutinib (40 mg QD, 80 mg QD, 160 mg QD, 160 mg BID, and 320 mg QD) were evaluated.","id":"OG000","title":"Part 1: Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"The Safety Analysis Set included all participants who received ≥ 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Month 9","title":"Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib","type":"PRIMARY","unitOfMeasure":"milligrams"}